Kezar Life Sciences, Inc. lost $7.66 per diluted share in fiscal year 2025. The change from the prior fiscal year is not meaningful, because that figure was zero or negative. Over the trailing 12 months, Q2 FY2025 through Q1 FY2026, the same line adds up to a loss of $6.17 per diluted share. The table below carries 10 fiscal years, from 2016 to 2025, and the quarters Kezar Life Sciences, Inc. has filed alongside them.
FY2025 annual
EPS (Diluted)-$7.66
YoYn/m
Source SEC Filings (10-K/10-Q)Latest period Q1 FY2026, ended Mar 31, 2026ReportedCurrency USD
Annual figures, oldest first. Point at a bar to read its period.
KZR EPS (Diluted) by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports.
Kezar Life Sciences, Inc. lost $7.66 per diluted share in fiscal year 2025.
Kezar Life Sciences, Inc. (KZR) reported a loss of $11.49 per diluted share in fiscal year 2024 and a loss of $7.66 per diluted share in fiscal year 2025. A growth rate is not meaningful here, because the earlier figure was zero or negative.
Kezar Life Sciences, Inc. (KZR) reported a loss of $6.17 per diluted share over the trailing 12 months, Q2 FY2025 through Q1 FY2026, summed from the four most recent quarterly filings.
Across the 10 fiscal years this page covers, Kezar Life Sciences, Inc. (KZR) diluted earnings per share went from -$26.56 in fiscal year 2016 to -$7.66 in fiscal year 2025.
Kezar Life Sciences, Inc. (KZR) reported -$0.78 in diluted earnings per share in Q1 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports. This page lists what Kezar Life Sciences, Inc. (KZR) reported on that line in every period on record.
